Literature DB >> 1747629

Orthopaedic surgeons and thromboprophylaxis.

.   

Abstract

Mesh：

Substances：

Year:  1991        PMID： 1747629      PMCID： PMC1671491          DOI： 10.1136/bmj.303.6811.1202-c

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  8 in total

1.  Orthopaedic surgeons and thromboprophylaxis.

Authors:  M D Laverick; S A Croal; R A Mollan
Journal:  BMJ       Date:  1991-09-07

2.  Total hip replacement and deep vein thrombosis. A venographic and necropsy study.

Authors:  A Planès; N Vochelle; M Fagola
Journal:  J Bone Joint Surg Br       Date:  1990-01

Review 3.  Prevention of venous thrombosis in patients undergoing major orthopaedic surgical procedures.

Authors:  J Hirsh; M Levine
Journal:  Br J Clin Pract Suppl       Date:  1989-01

4.  Adjusted versus fixed-dose subcutaneous heparin in the prevention of deep-vein thrombosis after total hip replacement.

Authors:  P F Leyvraz; J Richard; F Bachmann; G Van Melle; J M Treyvaud; J J Livio; G Candardjis
Journal:  N Engl J Med       Date:  1983-10-20       Impact factor: 91.245

5.  A randomized controlled trial of a low-molecular-weight heparin (enoxaparin) to prevent deep-vein thrombosis in patients undergoing elective hip surgery.

Authors:  A G Turpie; M N Levine; J Hirsh; C J Carter; R M Jay; P J Powers; M Andrew; R D Hull; M Gent
Journal:  N Engl J Med       Date:  1986-10-09       Impact factor: 91.245

6.  Efficacy of fixed minidose warfarin prophylaxis in total hip replacement.

Authors:  M J Fordyce; A S Baker; G E Staddon
Journal:  BMJ       Date:  1991-07-27

7.  Prevention of deep vein thrombosis after hip replacement: randomised comparison between unfractionated heparin and low molecular weight heparin.

Authors:  P F Leyvraz; F Bachmann; J Hoek; H R Büller; M Postel; M Samama; M D Vandenbroek
Journal:  BMJ       Date:  1991-09-07

8.  The antithrombotic activity and pharmacokinetics of enoxaparine, a low molecular weight heparin, in humans given single subcutaneous doses of 20 to 80 mg.

Authors:  A M Frydman; L Bara; Y Le Roux; M Woler; F Chauliac; M M Samama
Journal:  J Clin Pharmacol       Date:  1988-07       Impact factor: 3.126
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.